• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Calliditas Therapeutics AB

    9/17/24 7:55:03 AM ET
    $CALT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CALT alert in real time by email
    SC 13D/A 1 ea0214737-13da3asahi_call.htm AMENDMENT NO. 3 TO SCHEDULE 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13D

    (Amendment No. 3)*

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    CALLIDITAS THERAPEUTICS AB

    (Name of Issuer)

     

    Common Shares, quota value SEK 0.04 per Share and

    American Depositary Shares, each representing two Common Shares, quota value SEK 0.04 per Share

    (Title of Class of Securities)

     

    13124Q1061

    (CUSIP Number)

     

    Shinichiro Haga

    Lead Executive Officer and Senior General Manager, Corporate Strategy

    1-1-2 Yurakucho, Chiyoda-ku, Tokyo, Japan 100-0006

    Tel: +81-3-6699-3000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

      

    With a copy to:

    Benet J. O’Reilly, Esq.

    Adam J. Brenneman, Esq.

    Kimberly R. Spoerri, Esq.

    Cleary, Gottlieb, Steen & Hamilton LLP

    One Liberty Plaza

    New York, New York 10006

    (212) 225-2000

     

    September 13, 2024

    (Date of Event Which Requires Filing of Statement on Schedule 13D)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 

     

     

    1No CUSIP number exists for the underlying Common Shares, as the Common Shares are not traded in the United States. The CUSIP number 13124Q106 is only for the American Depositary Shares representing Common Shares.

     

     

     

     

     

     

    CUSIP No. 13124Q106 Page 2 of 5 Pages

     

    (1)

    Name of Reporting Persons:

    ASAHI KASEI CORPORATION

    (2)

    Check the Appropriate Box if a Member of a Group (See Instructions):

    (a) ☐ (b) ☒

    (3)

    SEC Use Only:

     

    (4)

    Source of Funds (See Instructions):

    OO

    (5)

    Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):

    ☐

    (6)

    Citizenship or Place of Organization:

    Japan

    NUMBER OF SHARES BENEFICIALLY OWNED BY
    EACH REPORTING PERSON WITH:
    (7)

    Sole Voting Power

    53,156,176(1)

    (8)

    Shared Voting Power

    0

    (9)

    Sole Dispositive Power

    53,156,176(1)

    (10)

    Shared Dispositive Power

    0

    (11)

    Aggregate Amount Beneficially Owned by Each Reporting Person:

    53,156,176(1)

    (12)

    Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):

    ☐

    (13)

    Percent of Class Represented by Amount in Row (11):

    98.38%

    (14)

    Type of Reporting Person (See Instructions):

    CO

     

     

    (1)See Item 5 of this Schedule 13D.

     

     

     

     

    CUSIP No. 13124Q106 Page 3 of 5 Pages

     

    ITEM 1. SECURITY AND ISSUER

     

    This Amendment No. 3 (the “Amendment”) amends the Schedule 13D filed with the Securities and Exchange Commission on May 27, 2024, as amended on September 3, 2024 and September 9, 2024 (the “Schedule 13D”), by AKC (as defined in Item 2), with respect to the ordinary shares, quota value SEK 0.04 (the “Shares”), of Calliditas Therapeutics AB, a company incorporated under the laws of Sweden (the “Company”), including Shares represented by American Depositary Receipts (“ADSs”). The principal executive offices of the Company are located at Kungsbron 1, D5, SE-111 22, Stockholm, Sweden. Capitalized terms used but not otherwise defined in this Amendment have the meanings ascribed to such terms in the Schedule 13D.

     

    This Amendment is being filed to report the increase in percentage of shares owned by AKC pursuant to the Subsequent U.S. Offering Period (as defined in Item 4). The Subsequent U.S. Offering Period expired on September 13, 2024. As a result of the Subsequent U.S. Offering Period and the concurrent subsequent period of the Swedish Offer (as defined in Item 4) in Sweden, AKC's percentage of beneficial ownership of Shares increased to 98.38%.

     

    ITEM 4. PURPOSE OF TRANSACTION.

     

    Item 4 is hereby amended and restated in its entirety as follows:

     

    “Offer

     

    On July 18, 2024, AKC filed a Schedule TO (as amended August 1, 2024 and August 13, 2024, and together with any subsequent amendments and supplements thereto, the “Schedule TO”) with the Securities and Exchange Commission (the “Commission”) in relation to the commencement of a tender offer to purchase all of the outstanding Shares, held by U.S. Persons (as defined in the Schedule TO) and all of the outstanding ADSs, each representing two Shares, whether or not held by U.S. Persons, of the Company, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated as of July 18, 2024, as amended (such offer, the “U.S. Offer”). The U.S. Offer was made in conjunction with an offer by AKC in Sweden directed to holders of Shares, but not holders of ADSs (the “Swedish Offer,” and together with the U.S. Offer, the “Offer”). The board of directors of the Company unanimously recommended the shareholders and ADS holders of the Company to accept the Offer. The recommendation is supported by an opinion provided by Lazard AB according to which the Offer is fair for the Company’s shareholders and ADS holders from a financial perspective.

     

    Completion of the Offer was subject to the following conditions: (1) the Offer being accepted to such extent that AKC becomes the owner of more than 90 percent of the Shares of the Company (on a fully diluted basis); (2) the receipt of all necessary regulatory, governmental or similar clearances, approvals and decisions, including from competition authorities and agencies screening foreign direct investments, in each case on terms that, in AKC’s opinion, are acceptable; (3) neither the Offer nor the acquisition of the Company being rendered wholly or partially impossible or significantly impeded as a result of legislation or other regulation, any decision of a court or a public authority, or any similar circumstance; (4) no circumstances having occurred that have a material adverse effect on the Company’s financial position, prospects or operations, including the Company’s sales, results, liquidity, equity ratio, equity or assets; (5) no information made public by the Company, or disclosed by the Company to AKC, being inaccurate, incomplete or misleading, and the Company having made public all information that should have been made public by the Company; (6) the Company not taking any action that is intended to impair the prerequisites for making or completing the Offer; and (7) no other party announcing an offer to acquire shares or ADSs of the Company on terms that are more favorable to the shareholders or ADS holders of the Company than the terms of the Offer.

     

     

     

     

    CUSIP No. 13124Q106 Page 4 of 5 Pages

     

    The foregoing description of the Offer and the transactions contemplated thereby does not purport to be complete and is qualified in its entirety by reference to the Schedule TO.

     

    On September 3, 2024, AKC amended Schedule TO disclosing, among other things, final results of the Offer and the satisfaction of the Offer conditions. AKC also disclosed that, on September 2, 2024, it accepted for purchase 1,028,600 ADSs, representing 2,057,200 Shares, and 42,988,491 Shares, for a total of 45,045,691 Shares. Following the announcement of the Offer and as previously disclosed, AKC acquired 5,367,206 Shares, corresponding to 9.93% of the outstanding Shares, outside the Offer and outside of the United States at prices not exceeding the price per share of SEK 208. AKC also disclosed the commencement of the subsequent U.S. offering period in accordance with Rule 14d-11 of the Act (the “Subsequent U.S. Offering Period”) and its intention to initiate compulsory redemption proceedings in accordance with the Swedish Companies Act (Sw. aktiebolagslagen (2005:551)).

     

    On September 13, 2024, the Subsequent U.S. Offering Period expired as scheduled. As a result, upon settlement of the Subsequent U.S. Offering Period and the concurrent subsequent offering period of the Swedish Offer, AKC will own 53,156,176 Shares, corresponding to a total of 98.38% of the outstanding Shares.

     

    On September 23, 2024, the Subsequent U.S. Offering Period will settle. The offer prices to be paid by AKC are SEK 208 per Share and SEK 416 per ADS for a total of SEK 570,602,032.

     

    Pursuant to a request from AKC, the Company has submitted a notice of termination to the ADS depositary, notified Nasdaq Global Select Market (“Nasdaq”) of its intention to voluntarily delist the ADSs and filed a Form 25, Notification of Removal from Listing and/or Registration with the Commission, thereby commencing the process of delisting the ADSs from Nasdaq and terminating the ADS program. Provided that the criteria for deregistration are met, the Company also intends to terminate its reporting obligations under the Securities Exchange Act of 1934, as amended, by filing the requisite documentation with the Commission.

     

    AKC has not made any decisions involving any changes to the Company’s business, the locations where the Company conducts its business or the Company’s management and employees, including their terms of employment. However, to realize efficiencies, the integration of AKC and the Company will likely entail some changes to the organization, operations and employees of the combined group. In the period following the completion of the Offer and following careful review of the needs of the combined business, AKC will determine the optimal structure of the combined company to continue to deliver success in the future.

     

    Starting on May 30, 2024, certain Shares have been purchased by or on behalf of AKC in the open market in Sweden. For more information regarding these purchases, see Item 5(c) of the Schedule 13D filed with the Commission on June 4, 2024.

     

    Irrevocable Undertakings

     

    In connection with the Offer, and as previously disclosed, AKC entered into the Irrevocable Undertakings with the Supporting Shareholders, pursuant to which the Supporting Shareholders agreed, among other things, to accept the Offer and to tender all of their Shares within five business days after the end of the initial Offer period, and not to withdraw such acceptance, upon the terms and subject to the conditions of the Irrevocable Undertakings. The Irrevocable Undertakings provided for the termination upon certain circumstances, including upon withdrawal of the Offer by AKC or if AKC has not withdrawn the Offer or declared the Offer unconditional by October 31, 2024.

     

    The foregoing description of the Irrevocable Undertakings does not purport to be complete and is qualified in its entirety by reference to the full text of each of the Irrevocable Undertakings, copies of which are filed herewith as Exhibits 2, 3, 4, 5, 6, 7, 8, 9 and 10.”

     

     

     

     

    CUSIP No. 13124Q106 Page 5 of 5 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Schedule 13D is true, complete, and correct.

     

    Dated: September 17, 2024

     

      By: /s/ Shinichiro Haga
        Name:  Shinichiro Haga
        Title: Attorney-in-Fact pursuant to Power of Attorney
      attached to this Schedule 13D

     

     

     

    Get the next $CALT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CALT

    DatePrice TargetRatingAnalyst
    6/20/2023$60.00Buy
    H.C. Wainwright
    3/1/2023$18.00Neutral
    Guggenheim
    12/20/2021$52.00 → $62.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CALT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm

      STOCKHOLM, Sept. 16, 2024 /PRNewswire/ -- Nasdaq Stockholm has decided that Calliditas Therapeutics AB (publ) will be delisted from Nasdaq Stockholm. The last day of trading in the share will be on Thursday, October 10, 2024. For further information, please contact: Åsa Hillsten, Head of IR & Sustainability, Calliditas Tel.: +46 76 403 35 43, Email: [email protected] The information was sent for publication, through the agency of the contact person set out above, on September 16, 2024 at 15:30 CET. About Calliditas Calliditas Therapeutics is a biopharma company headquartered in Stockholm, Sweden, focused on identifying, developing, and commercializing novel treatments in orphan in

      9/16/24 9:46:00 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Notice of extraordinary meeting of Calliditas Therapeutics AB (publ)

      STOCKHOLM, Sept. 3, 2024 /PRNewswire/ -- The shareholders of Calliditas Therapeutics AB (publ) ("Calliditas Therapeutics"), Reg. No. 556659-9766, with registered office in Stockholm, are summoned to the extraordinary general meeting on Monday 30 September 2024 at 12:00 p.m. CEST at Advokatfirman Vinge's premises on Smålandsgatan 20, SE-111 46, Stockholm, Sweden. Registration starts at 11:30 a.m. CEST. Background Asahi Kasei Corporation ("Asahi Kasei"), which has announced that the public offer made regarding the company's shares has been accepted to such extent that Asahi Kasei becomes the owner of more than 90 per cent of the shares and votes in the company, has requested the board of dire

      9/3/24 7:13:00 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei

      STOCKHOLM, Sept. 3, 2024 /PRNewswire/ -- Following the announcement by Asahi Kasei Corporation ("Asahi Kasei") on September 2, 2024 that it controls more than 90 percent of the outstanding shares of Calliditas Therapeutics AB (NASDAQ:CALT) ("Calliditas" or the "Company"), and declared its offers to purchase all of the outstanding Common Shares and ADSs of Calliditas unconditional and intends to initiate compulsory redemption of the remaining shares of the Company, the Board of Directors of Calliditas has resolved, in accordance with a request from Asahi Kasei, to take certain corporate actions. Delisting of Common Shares and Delisting, Deregistration, and Termination of ADS Program In light

      9/3/24 6:31:00 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALT
    Financials

    Live finance-specific insights

    See more
    • Calliditas Interim Report January to June 2024

      STOCKHOLM, Aug. 13, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ:CALT) (STO: CALTX) : April to June 2024 (compared to April to June 2023) Net sales amounted to SEK 559.8 million, of which TARPEYO® net sales amounted to SEK 493.4 million, for the three months ended June 30, 2024. For the three months ended June 30, 2023, net sales amounted to SEK 269.4 million, of which TARPEYO net sales amounted to SEK 259.2 million.Operating loss amounted to SEK 31.5 million and SEK 75.2 million for the three months ended June 30, 2024, and 2023, respectively. However, expenses related to the Asahi Kasei offer and expenses related to provisions for social security contribution for incentive prog

      8/13/24 1:22:00 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Invitation to the presentation of Calliditas's interim report January - June 2024

      STOCKHOLM, Aug. 5, 2024 /PRNewswire/ -- Calliditas's interim report for the second quarter, April - June 2024 will be published in Swedish and English on Tuesday 13 August 2024 at 07.00 a.m. CET. A combined audio cast and telephone conference with the opportunity to ask questions will be held at 14.30 p.m. CET on the same day, with CEO Renée Aguiar-Lucander and CFO Fredrik Johansson, CMO Richard Philipson and President North America Maria Törnsén. The presentation will be given in English. Link to the webcast:  https://ir.financialhearings.com/calliditas-therapeutics-q2-report-2024 To participate via conference call please register via this link: https://conference.financialhearings.com/tel

      8/5/24 1:19:00 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)

      STOCKHOLM, June 17, 2024 /PRNewswire/ -- The following resolutions were passed at Calliditas Therapeutics AB (publ) ("Calliditas") annual general meeting held today, on 17 June 2024, in Stockholm. Adoption of income statement and balance sheet for the financial year 2023 and discharge from liability The annual general meeting resolved to adopt the income statement and the consolidated income statement for the financial year 2023 as well as the balance sheet and consolidated balance sheet as of 31 December 2023. The members of the Board of Directors and the CEO were discharged from liability for the financial year 2023. Allocation of profit or loss                                            

      6/17/24 12:01:00 PM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Calliditas Therapeutics AB with a new price target

      H.C. Wainwright initiated coverage of Calliditas Therapeutics AB with a rating of Buy and set a new price target of $60.00

      6/20/23 7:20:21 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Calliditas Therapeutics AB with a new price target

      Guggenheim initiated coverage of Calliditas Therapeutics AB with a rating of Neutral and set a new price target of $18.00

      3/1/23 6:14:34 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Calliditas Therapeutics with a new price target

      HC Wainwright & Co. reiterated coverage of Calliditas Therapeutics with a rating of Buy and set a new price target of $62.00 from $52.00 previously

      12/20/21 6:22:01 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALT
    SEC Filings

    See more
    • SEC Form 15F-12B filed by Calliditas Therapeutics AB

      15F-12B - Calliditas Therapeutics AB (0001795579) (Filer)

      9/23/24 4:44:35 PM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Calliditas Therapeutics AB

      25-NSE - Calliditas Therapeutics AB (0001795579) (Subject)

      9/20/24 4:45:11 PM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC TO-T/A filed by Calliditas Therapeutics AB

      SC TO-T/A - Calliditas Therapeutics AB (0001795579) (Subject)

      9/18/24 9:02:28 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for TARPEYO issued to CALLIDITAS THERAPEUTICS AB

      Submission status for CALLIDITAS THERAPEUTICS AB's drug TARPEYO (ORIG-1) with active ingredient BUDESONIDE has changed to 'Approval' on 12/15/2021. Application Category: NDA, Application Number: 215935, Application Classification: Type 5 - New Formulation or New Manufacturer

      12/20/21 3:40:41 PM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALT
    Leadership Updates

    Live Leadership Updates

    See more
    • Calliditas Therapeutics appoints Maria Törnsén as President North America

      STOCKHOLM, Jan. 7, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ:CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that Maria Törnsén has been appointed to the position of President North America. Ms Törnsén will be responsible for all US based operations and will report to the CEO. Maria Törnsén has broad commercial leadership experience having spent more than 20 years in the biopharma industry in senior commercial roles. Most recently Ms Törnsén held the position of Chief Commercial Officer at Passage Bio, prior to which she was SVP General Manager US at Sarepta Therapeutics. Prior to joining Sarepta she serv

      1/7/24 11:19:00 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celularity Appoints Industry Leader Diane Parks to its Board of Directors

      FLORHAM PARK, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks, an executive with deep experience in the commercialization of novel immuno-oncology therapies, has led the successful launch of numerous hematology and cancer therapies at large pharmaceutical and biotech companies, including Kite Pharma, Inc. (now part of Gilead Sciences, Inc.), Amgen Inc., and Genentech, Inc. (now part of Roche Holdings, Inc.). "It is with great pleasure we welcome Diane to the Cel

      6/3/22 8:00:00 AM ET
      $CALT
      $CELU
      $CTIC
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phathom Pharmaceuticals Announces Appointment of Molly Henderson as Chief Financial and Business Officer

      FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Molly Henderson to the position of Chief Financial and Business Officer. Ms. Henderson will join the Company effective April 5, 2022.       Ms. Henderson most recently served as Chief Financial Officer of UroGen Pharma (NASDAQ:URGN), a commercial-stage biopharmaceutical company focused on building novel treatments for specialty cancers and urologic disease. She brings over two decades of global finance expertise and has

      3/22/22 8:02:00 AM ET
      $CALT
      $PHAT
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Calliditas Therapeutics AB

      SC 13D/A - Calliditas Therapeutics AB (0001795579) (Subject)

      9/23/24 7:32:15 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Calliditas Therapeutics AB

      SC 13D/A - Calliditas Therapeutics AB (0001795579) (Subject)

      9/17/24 7:55:03 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Calliditas Therapeutics AB

      SC 13G/A - Calliditas Therapeutics AB (0001795579) (Subject)

      9/11/24 7:42:16 PM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care